Skip to main content
SpringerLink
Log in

Sclérodermie systémique et sclérodermies cutanées

  • Chapter
Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées

  • 549 Accesses

Abstrait

L’incidence de la maladie est de 2 à 20 par million d’habitants et par an avec une nette prédominance féminine (sex-ratio de 8F/1H). Selon des estimations récentes, la prévalence dans la population française est de 11 à 16 cas pour 100 000 habitants, ce qui permet d’;estimer à près de 6000 le nombre de personnes atteintes de ScS. La maladie survient avec prédilection entre 30 et 50 ans mais peut être observée à tout âge. La ScS de l’enfant est rare: moins de 2% des cas avant 10 ans et moins de 8% des cas avant ’âge de 20 ans1. Son début est plus tardif chez ’homme que chez la famme. La ScS a une distribution mondiale mais une fréquence moindre au sein de la population asiatique2.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Larregue M, Canuel C, Bazex J et al. Sclérodermie systémique de ’enfant: à propos de 5 observations. Revue de la littérature. Ann Dermatol Venereol 1983; 110:317–326.

    PubMed  CAS  Google Scholar 

  2. Silman AJ, Newman J. Epidemiology of systemic sclerosis. Curr Opin Rheumatol 1996; 8: 585–589.

    Article  PubMed  CAS  Google Scholar 

  3. Furst DE, Clements PJ, Steen VD et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25:84–88.

    PubMed  CAS  Google Scholar 

  4. Kluger N, Gati S, Molinari E, Frances C. [Lung disease in systemic scleroderma]. Ann Dermatol Venereol 2005; 132:905–914.

    PubMed  CAS  Google Scholar 

  5. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  6. Manganelli P, Salaffi F, Carotti M et al. Pulmonary hypertension in rheumatic diseases. Minerva Med 1999; 90:59–72.

    PubMed  CAS  Google Scholar 

  7. Puissant A, Roujeau J, Modigliani R et al. Les symptômes digestifs de la sclérodermie. Ann Dermatol Venereol 1978; 105:715–720.

    Google Scholar 

  8. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265–1282.

    Article  PubMed  CAS  Google Scholar 

  9. Marguerie C, Kaye S, Vyse T et al. Malabsorption caused by coeliac disease in patients who have scleroderma. Br J Rheumatol 1995; 34:858–861.

    Article  PubMed  CAS  Google Scholar 

  10. Shawis TN, Chaloner C, Herrick AL, Jayson MI. Pancreatic function in systemic sclerosis. Br J Rheumatol 1996; 35:298–299.

    Article  PubMed  CAS  Google Scholar 

  11. Marie I, Levesque H, Tranvouez JL et al. Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology 2001; 40:102–106.

    Article  PubMed  CAS  Google Scholar 

  12. Steen VD, Syzd A, Johnson JP et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005; 32:649–655.

    PubMed  Google Scholar 

  13. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996; 22:861–878.

    Article  PubMed  CAS  Google Scholar 

  14. Ferri C, Giuggiolo D, Sebastiani M et al. Heart involvement and systemic sclerosis. Lupus 2005; 14:702–707.

    Article  PubMed  CAS  Google Scholar 

  15. Hachulla E. Traitement de ’hypertension artérielle pulmonaire associée à la sclérodermie systémique. Rev Med Interne 2004; 25:195–200.

    PubMed  CAS  Google Scholar 

  16. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2–10.

    Article  PubMed  Google Scholar 

  17. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 1988; 15:894–898.

    PubMed  CAS  Google Scholar 

  18. Hachulla E, Dubucquoi S. Intérêt des anticorps antinucléaires pour le diagnostic, la classification et le pronostic de la sclérodermie systémique. Rev Med Interne 2004; 25:442–447.

    PubMed  CAS  Google Scholar 

  19. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S et al. Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 1986; 115:393–401.

    Article  PubMed  CAS  Google Scholar 

  20. Katayama I, Otoyama K, Kondo S et al. Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol 1990; 23:198–201.

    Article  PubMed  CAS  Google Scholar 

  21. Karmochkine M, Cacoub P, Dorent R et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996; 23:286–290.

    PubMed  CAS  Google Scholar 

  22. Artlett CM. Immunology of systemic sclerosis. Front Biosci 2005; 10:1707–1719.

    Article  PubMed  CAS  Google Scholar 

  23. LeRoy EC, Trojanowska MI, Smith EA. Cytokines and human fibrosis. Eur Cytokine Netw 1990; 1:215–219.

    PubMed  CAS  Google Scholar 

  24. Noble NA, Harper JR, Border WA. In vivo interactions of TGF-beta and extracellular matrix. Prog Growth Factor Res 1992; 4:369–382.

    Article  PubMed  CAS  Google Scholar 

  25. Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167–4171.

    Article  PubMed  CAS  Google Scholar 

  26. Hasegawa M, Fujimoto M, Takehara K, Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005; 39:1–7.

    Article  PubMed  CAS  Google Scholar 

  27. Haustein UF, Anderegg U. Pathophysiology of scleroderma: an update. J Eur Acad Dermatol Venereol 1998; 11:1–8.

    Article  PubMed  CAS  Google Scholar 

  28. Hayakawa I, Hasagawa M, Matsushita T et al. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology 2005; 44:873–878.

    Article  PubMed  CAS  Google Scholar 

  29. Humbert P, Dupond JL, Vuitton D, Agache P. Dermatological autoimmune diseases and the multiple autoimmune syndromes. Acta Derm Venereol Suppl (Stockh) 1989; 148:1–8.

    CAS  Google Scholar 

  30. Cho MM, Jimenez SA, Johnson BA et al. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 1994; 62: 73–81.

    PubMed  CAS  Google Scholar 

  31. Sawaya HH, Jimenez SA, Artlett CM. Quantification of foetal microchimeric cells in clinically affected and unaffected skin patients with systemic sclerosis. Rheumatology 2004; 43:965–968.

    Article  PubMed  CAS  Google Scholar 

  32. Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L. Treatment of ischaemic ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol (Stockh) 1996; 76:236–238.

    CAS  Google Scholar 

  33. Hashimoto H. Steroid pulse therapy for progressive systemic sclerosis. Intern Med 1996; 35: 525–526.

    PubMed  CAS  Google Scholar 

  34. Kallenberg CGM, Jansenn HM, Elema JD, The TH. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 1984; 86: 489–492.

    Article  PubMed  CAS  Google Scholar 

  35. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425–434.

    PubMed  CAS  Google Scholar 

  36. Olschewski H, Simmoneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322–329.

    Article  PubMed  CAS  Google Scholar 

  37. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896–903.

    Article  PubMed  CAS  Google Scholar 

  38. Schachna L, Braunstein NA, Dauber JH et al. Lung transplantation for systemic sclerosis compared with idiopathic pulmonary fibrosis: increased early mortality but comparable survival at one year. Arthritis Rheum 2002; 46suppl:S382.

    Google Scholar 

  39. Kanekura T, Fukumaru S, Matsushita S et al. Successful treatment of scleroderma with PUVA therapy. J Dermatol 1996; 23:455–459.

    PubMed  CAS  Google Scholar 

  40. Von Kobyletzki G, Uhle A, Pieck C et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV A1 phototherapy. Arch Dermatol 2000; 136:275–276.

    Article  Google Scholar 

  41. Cohen S, Laufer I, Snape WJ et al. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology 1980; 79:155–166.

    PubMed  CAS  Google Scholar 

  42. Freneaux B, Freneaux J, Buyse N, Le Van Quyen H. Silicose associée à la sclerodermie. Nouv Presse Med 1975; 4:2087–2090.

    PubMed  CAS  Google Scholar 

  43. Moulin G, Rety J, Paliard P et al. Aspects sclérodermiformes de ’acro-ostéolyse professionnelle. Ann Dermatol Syphiligr (Paris) 1974; 101:33–44.

    CAS  Google Scholar 

  44. Kahn ME. Connectivite mixte ou syndrome de Sharp. Concepts actuels. Presse Med 1983; 12:2975–2976.

    PubMed  CAS  Google Scholar 

  45. Peterson LS, Nelson AM, Su WPD. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70:1068–1076.

    Article  PubMed  CAS  Google Scholar 

  46. Weide B, Schittek B, Klyscz T et al. Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesion skin by polymerase chain reaction. Br J Dermatol 2000; 143:780–785.

    Article  PubMed  CAS  Google Scholar 

  47. Morita A, Kobayashi K, Isomura I et al. Ultraviolet A1 (340–400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43:670–674.

    Article  PubMed  CAS  Google Scholar 

  48. Von Kobyletzki G, Uhle A, Pieck C et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UVA1 phototherapy. Arch Dermatol 2000; 136:275–276.

    Article  Google Scholar 

  49. Cribier B, Faradji L, Le Coz C et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 1995; 191:25–31.

    Article  PubMed  CAS  Google Scholar 

  50. Czarnecki DB, Taft EH. Generalized morphoea successfully treated with salazopyrine. Acta Derm Venereol (Stockh) 1982; 62:81–82.

    CAS  Google Scholar 

  51. Falanga V, Medsger TA Jr. D-Penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126:609–612.

    Article  PubMed  CAS  Google Scholar 

  52. Neuhofer J, Fritsch P. Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm Venereol (Stockh) 1984; 64:171–174.

    CAS  Google Scholar 

  53. Peter RU, Ruzicka T, Eckert F. Low dose cyclosporine A in the treatment of distabling morphea. Arch Dermatol 1991; 127:1420–1421.

    Article  PubMed  CAS  Google Scholar 

  54. Uziel Y, Feldman BM, Krafchik BR et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136:91–95.

    Article  PubMed  CAS  Google Scholar 

  55. Kreuter A, Gambichler T, Avermaete A et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in chilhood morphea. Pediatr Dermatol 2001; 18:241–245.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Philippe Humbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Éve Puzenat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Humbert, P., Puzenat, É. (2007). Sclérodermie systémique et sclérodermies cutanées. In: Manifestations dermatologiques des connectivites, vasculites et affections systémiques apparentées. Springer, Paris. https://doi.org/10.1007/978-2-287-33886-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-33886-1_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-33885-4

  • Online ISBN: 978-2-287-33886-1

Publish with us

Policies and ethics

Search

Navigation